Experience with use of recombinant activated factor VII

Divanon, Fabienne; Hecquard, C.; Borel‐Derlon, Annie

doi:10.1046/j.1365-2710.2002.00394.x

Cited by 26 publications

(31 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors of that report concluded that rFVIIa did not appear to be immediately responsible for the thrombosis, noting that after administration of rFVIIa, the ECMO circuit was functioning well and only after APCC was given did the thrombosis occur. The association of APCC with thrombotic events has been noted in the past (17).…”

Section: Discussionmentioning

confidence: 99%

Use of recombinant factor VIIa for refractory hemorrhage during extracorporeal membrane oxygenation*

Dominguez

Mitchell

Friess

et al. 2005

Pediatric Critical Care Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Use of recombinant factor VIIa for refractory hemorrhage during extracorporeal membrane oxygenation*

Dominguez

Mitchell

Friess

et al. 2005

Pediatric Critical Care Medicine

View full text Add to dashboard Cite

show abstract

“…The dose regimen used in these two patients was 100 μ g kg −1 every 2 h for three doses day −1 ; the duration of treatment varied according to the severity of the bleeding. In addition, another patient with inhibitor to FV was treated with rFVIIa for a severe knee joint bleed [3]. rFVIIa 80 μ g kg −1 was given every 3 h for three doses on the first day, every 4 h for three doses on the second day, and every 4 h for two doses on the third day.…”

Section: Discussionmentioning

confidence: 99%

The use of activated recombinant coagulation factor VII during haemarthroses and synovectomy in a patient with congenital severe factor V deficiency

et al. 2005

View full text Add to dashboard Cite

Factor V deficiency is a rare hereditary bleeding disorder. Currently, FV concentrates are not available, and the treatment of spontaneous bleeding or bleeding associated with invasive procedures is transfusion of fresh frozen plasma (FFP). However, FFP transfusion can lead to the development of inhibitor to FV, and is associated with several potential transfusion reactions including allergic reactions. We report a patient with congenital severe FV deficiency with repeated haemarthroses of a shoulder joint, and progressively severe allergic reactions to FFP transfusions. In addition, the patient also developed acute pulmonary oedema. Activated recombinant coagulation factor VII (rFVIIa) was used as an alternative haemostatic agent to FFP. We describe the use of rFVIIa in this patient during haemarthroses, synovectomy, and physiotherapy.

show abstract

“…Only English language literature was considered. Fifty articles were subsequently identified [10–57]. Underlying coagulopathy and/or the results of rFVIIa treatment in congenital haemophilia patients with inhibitors could be ascertained in only 46 of the 50 articles identified.…”

Section: Methodsmentioning

confidence: 99%

Surgical Experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX

2011

View full text Add to dashboard Cite

Patients with congenital haemophilia with inhibitors are at risk of peri-operative bleeding complications, since replacement of the missing coagulation factor is ineffective, presenting a therapeutic challenge in elective or emergency surgery. Therefore, the management of peri-operative bleeding requires the use of bypassing agents, such as recombinant activated FVII (rFVIIa, NovoSeven(®) ). This article presents an updated evaluation of the safety and effectiveness of rFVIIa in the treatment of peri-operative bleeding in this patient population. Surgical and other medical procedures managed with rFVIIa from two randomized clinical trials, the Hemophilia Research Society/Hemophilia and Thrombosis Research Society (HRS/HTRS) registry databases and the medical literature were analysed. There were 395 rFVIIa-treated procedures (261 surgical, 89 dental and 45 other medical procedures) reported for 263 congenital haemophilia patients with inhibitors. In trials, initial rFVIIa dosing was 35-90 mcg kg(-1) bolus injection or 50 mcg kg(-1) h(-1) continuous infusion. Dosing in the registries and literature was more variable. Recombinant FVIIa effectiveness was comparable across data sources, with an overall rate of 84% (333/395). The incidence of thrombotic events was very low (0.4% of patients and 0.025% of procedures). Prior to the US approval of rFVIIa in 1999, surgical procedures in congenital haemophilia patients with inhibitors were often considered too risky. Recombinant FVIIa has consistently demonstrated effectiveness in treatment of bleeding in these patients during such procedures. Thrombotic events were rare. This analysis confirms the value of corroborating clinical trial results with post-marketing surveillance registries to assess small patient populations with clinically challenging management decisions.

show abstract

Experience with use of recombinant activated factor VII

Cited by 26 publications

References 36 publications

Use of recombinant factor VIIa for refractory hemorrhage during extracorporeal membrane oxygenation*

Use of recombinant factor VIIa for refractory hemorrhage during extracorporeal membrane oxygenation*

The use of activated recombinant coagulation factor VII during haemarthroses and synovectomy in a patient with congenital severe factor V deficiency

Surgical Experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX

Contact Info

Product

Resources

About